The Online Investor
OLI Premium
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Sat., May. 30, 6:35 AM

Slide #12. TransMedics Group, Inc. Secondary Offering

Company: TransMedics Group, Inc. (NASDAQ:TMDX)
Date announced: 5/26/2020
Shares Offered: 5,000,000
Date of Pricing: 5/26/2020
Price Per Share: $14.00
Secondary Offering Details: TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, announced today the commencement of a proposed public offering of $60 million of its shares of common stock. All of the shares will be offered by TransMedics. TransMedics also expects to grant the underwriters a 30-day option to purchase additional shares of its common stock in an amount of up to 15 percent of the number of shares sold in the offering. -updated 5/26- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, announced today the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a price to the public of $14.00 per share. All of the shares are being offered by TransMedics. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by TransMedics, are expected to be $70.0 million. The offering is expected to close on May 29, 2020, subject to the satisfaction of customary closing conditions. In addition, TransMedics has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock at the public offering price, less underwriting discounts and commissions.

TransMedics is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. Co. developed the Organ Care System (“OCS”) to replace a decades-old standard of care. The OCS represents a paradigm shift that transforms organ preservation for transplantation from a static state to a dynamic environment that enables new capabilities, including organ optimization and assessment. Co.'s OCS technology replicates many aspects of the organ's natural living and functioning environment outside of the human body.

TMDX SEC Filing Email Alerts Service

Open the TMDX Page at The Online Investor »

Company Name:  TransMedics Group Inc
Website:  www.transmedics.com
Sector:  Medical Instruments & Supplies
Number of ETFs Holding TMDX:  15
Total Market Value Held by ETFs:  $14.60M
Total Market Capitalization:  $299.00M
% of Market Cap. Held by ETFs:  4.88%
 

Open the TMDX Page at The Online Investor (in a new window) »

May 30, 2020    6:35 AM Eastern
Quotes delayed 20 minutes



Strong Buy (3.60 out of 4)
69th percentile
(ranked higher than approx. 69% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2020, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.